Suppression of histidine decarboxylase activity in rat oxyntic mucosa by beraprost sodium, a prostacyclin analogue.
Prostaglandins (PGs) affect various aspects of gastric functions. In the present study the orally administered PGI2 derivative beraprost sodium (TRK-100.1 micrograms per kg body weight) decreased oxyntic histidine decarboxylase activity without changing serum gastrin levels. Antral pH increased 4 hr after treatment. Beraprost also decreased the pentagastrin-induced histidine decarboxylase activity at the same dose. Serum levels of secretin, somatostatin and glucose, and oxyntic mucosal levels of histamine and somatostatin, showed no significant change after treatment with beraprost. These results suggest that the response of oxyntic histidine decarboxylase to gastrin is modified by one or more prostanoids including PGI2. This mechanism might play a role in gastric mucosal protection.
Kaneko
T
T
First Department of Surgery, Gunma University School of Medicine, Japan.
Nagamachi
Y
Y
Matsuzaki
S
S
D000818:Animals; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D011464:Epoprostenol / Q000031:analogs & derivatives* / Q000494:pharmacology; D005755:Gastrins / Q000097:blood / Q000187:drug effects / Q000378:metabolism; D006131:Growth Inhibitors / Q000494:pharmacology; D006632:Histamine / Q000378:metabolism; D006640:Histidine Decarboxylase / Q000187:drug effects / Q000378:metabolism*; D006863:Hydrogen-Ion Concentration; D008297:Male; D010295:Parietal Cells, Gastric / Q000187:drug effects / Q000378:metabolism*; D010418:Pentagastrin / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D012633:Secretin / Q000097:blood / Q000187:drug effects; D013004:Somatostatin / Q000097:blood / Q000187:drug effects / Q000378:metabolism
D001786:Blood Glucose; D005755:Gastrins; D006131:Growth Inhibitors; D012633:Secretin; C048081:beraprost; D013004:Somatostatin; D006632:Histamine; D011464:Epoprostenol; D006640:Histidine Decarboxylase; D010418:Pentagastrin